Full-Time

Project Engineer

Globus Medical

Globus Medical

1,001-5,000 employees

Develops musculoskeletal implants and enabling technologies

No salary listed

King of Prussia, PA, USA

In Person

Category
Biology & Biotech (1)
Required Skills
CAD
PTC Creo
GD&T
Requirements
  • Three to seven years’ experience in mechanical design engineering; Medical device experience strongly preferred
  • Bachelor’s Degree in Mechanical Engineering, Biomedical Engineering or a similar degree
  • Proficiency in Pro/E software or similar CAD software for design and drafting; knowledge of GD&T
  • Knowledge of risk analysis techniques
  • Strong verbal and written communication skills
  • Well organized, detail oriented, and team player capable of working in a deadline driven environment
  • Experience in preparing reports and managing project budgets
  • Strong knowledge of Microsoft Office
  • Ability to attend surgeries and/or labs
Responsibilities
  • Obtaining market feedback from surgeons and other customers to determine functional and design specifications for new product development
  • Creating and maintaining project plans and FDA compliant Design history Files (DHF) for each project
  • Managing all aspects of assigned projects to ensure timely completion of tasks while remaining in full compliance with Globus quality system and other applicable regulatory bodies
  • Designing and developing instruments and implants using Pro/E software
  • Working with in-house prototype shop and outside vendors for rapid prototyping and evaluation
  • Performing design verification and validation activities to ensure designs meet specifications
  • Collaborating with marketing and product managers to develop forecasts and market plans
  • Assisting in the writing of regulatory applications to the FDA and other regulatory bodies
  • Coordination with the operations department to setup manufacturing and/or purchasing as appropriate for each project
  • Participating in product introductions through sales training, customer calls/visits, etc.
  • Maintaining diligent post introduction monitoring to address and customer requests for changes
  • Researching industry and direct competitors on an ongoing basis to ensure that Globus has cutting edge technology in all markets entered
  • Adhering to the letter and spirit of the company Code of Conduct, the AdvaMed Code, MedTech Code, and all other company policies. Ensure Compliance with applicable governmental laws, rules, and regulations, both in the United States and internationally, by completing introductory and annual training and maintaining knowledge of compliance as it applies to your role
  • Representing the company in a professional manner and uphold the highest standards of ethical business practices and socially responsible conduct in all interactions with other employees, customers, suppliers, and other third parties of Globus
Desired Qualifications
  • Medical device experience strongly preferred

Globus Medical makes medical devices for musculoskeletal issues, especially spine, orthopedic, and neurosurgical care. Its products fall into two groups: Musculoskeletal Solutions with implantable devices, biologics, and surgical instruments, and Enabling Technologies with imaging, navigation, and robotics that help plan, guide, and analyze surgeries. The company stands out by offering an integrated platform that combines implants with enabling technologies to improve surgical precision and outcomes. Its goal is to help patients recover from musculoskeletal problems while expanding its product lines and geographic reach.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Lower Providence Township, Pennsylvania

Founded

2003

Simplify Jobs

Simplify's Take

What believers are saying

  • US spine business achieved third consecutive quarter of double-digit growth in Q1 2026.
  • Management signals tuck-in M&A strategy to drive robotics adoption and international expansion.
  • Analyst upgrades to $114–$115 price targets reflect confidence in 2026 guidance execution.

What critics are saying

  • Medtronic's 40% spine market share enables aggressive pricing that compresses Globus margins.
  • Enabling technologies adoption lags guidance; base business growth of 13.2% signals underperformance.
  • CMS reimbursement cuts of 10–15% on spinal procedures threaten $160–240M annual revenue.

What makes Globus Medical unique

  • ExcelsiusHub navigation system enhances robotic spine surgery precision and adoption rates.
  • Nevro acquisition expands neuromodulation portfolio beyond core spine and orthopedic implants.
  • NuVasive merger creates comprehensive musculoskeletal solutions across spine, trauma, and joint reconstruction.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Yahoo Finance
Mar 27th, 2026
Wells Fargo rates Globus Medical overweight with $104 target, raises EPS outlook to $4.40-$4.50

Wells Fargo has initiated coverage of Globus Medical with an Overweight rating and a $104 price target. The medical device company, which develops solutions for musculoskeletal disorders, recently reported strong fourth-quarter results with earnings per share of $1.28, beating the 96 cent consensus estimate, and revenue of $826.4 million versus $803.29 million expected. Chief executive Keith Pfeil highlighted double-digit sales and earnings growth in the fourth quarter, driven by expansion across the company's portfolio, including its spine business. Globus Medical raised its full-year 2026 earnings guidance to $4.40-$4.50 per share from $4.30-$4.40, above the $4.24 consensus. The company expects 2026 revenue of $3.18 billion to $3.22 billion.

AD HOC NEWS Portal Aktiengesellschaft
Mar 24th, 2026
Globus Medical Inc stock faces board shakeup as John DeFord steps down amid strong analyst outlook.

Globus Medical Inc stock faces board shakeup as John DeFord steps down amid strong analyst outlook. 24.03.2026 - 07:15:02 | ad-hoc-news.de Globus Medical Inc (ISIN: US3795772082) announced the immediate departure of board member John DeFord, sparking investor interest in governance changes at the medical device leader. The NYSE-listed GMED stock traded at 87.21 USD on March 23, 2026, with analysts maintaining an 'Outperform' consensus and a 109.31 USD average target, signaling 25% upside potential for US investors eyeing musculoskeletal innovations. Globus Medical Inc, a key player in musculoskeletal medical devices, disclosed the sudden resignation of board member John DeFord effective immediately on March 23, 2026. This governance shift comes as the company maintains robust growth momentum from its recent Q4 2025 earnings, where revenue hit 826.4 million USD, surpassing estimates. US investors should note this development against the backdrop of a strong analyst consensus rating the GMED stock as 'Outperform' with significant upside, highlighting strategic stability in the competitive spine and orthopedics market. As of: 24.03.2026 By Dr. Elena Voss, Senior MedTech Analyst - Tracking leadership transitions in US medical device firms reveals critical insights into innovation pipelines and M&A strategies for long-term shareholder value. Board departure signals potential strategic pivot. John DeFord's exit from Globus Medical's board marks a notable change in the company's oversight structure. DeFord, whose tenure contributed to key decisions in product development and partnerships, stepped down without specified reasons, per the company's filing. This move prompts questions about fresh perspectives in leadership as Globus navigates expanding demand for spinal implants and biologics. The timing aligns with recent positive earnings, where Q4 revenue exceeded expectations by over 24 million USD. Investors view such board refreshes as opportunities for injecting new expertise, particularly in AI-driven orthopedics and minimally invasive surgeries. For US portfolios, this underscores Globus's resilience in a sector projected to grow amid aging demographics. Market reaction remained measured, with the GMED stock closing at 87.21 USD on the NYSE, up 1.10% over five days. This stability reflects confidence in management's track record post the NuVasive merger, which bolstered the company's portfolio. Official source Find the latest company information on the official website of Globus Medical Inc. Recent earnings bolster investor confidence. Globus Medical's Q4 2025 results, reported on February 24, 2026, showcased revenue of 826.4 million USD against FactSet estimates of 801.7 million USD. Adjusted earnings rose in line with guidance, prompting the company to reaffirm 2026 revenue expectations at 3.18-3.22 billion USD. This performance highlights strength in core musculoskeletal solutions, including implants for spinal and orthopedic procedures. The company also updated its 2026 adjusted EPS guidance to 4.40-4.50 USD, topping consensus of 4.17 USD. Such beats signal operational efficiency and successful integration of acquired technologies. US investors benefit from this trajectory, as Globus's 6,000-strong workforce drives innovation in neurosurgical tools. Analyst upgrades followed, with Needham lifting its price target to 114 USD and Truist to 115 USD, both retaining Buy ratings. These updates reflect optimism around product roadmap and M&A pursuits signaled in the earnings call. Sentiment and reactions Why the market reacts to governance changes now. In the medtech sector, board compositions influence innovation pace and regulatory navigation. DeFord's departure, announced via Reuters on March 23, 2026, draws attention as Globus pursues M&A amid a consolidating industry. Investors monitor such shifts for signs of accelerated growth or risk mitigation. The GMED stock's year-to-date decline of 0.11% on the NYSE contrasts with a 2.88% five-day gain, indicating short-term resilience. Consensus from 15 analysts points to 109.31 USD average target, a 25.34% premium to the 87.21 USD close. This gap underscores market focus on execution rather than isolated events. Broader context includes insider sales in February, totaling millions, yet balanced by buyback program updates. These dynamics keep US investors engaged, particularly those betting on spine surgery demand driven by demographics. Relevance for US investors in medtech growth. US investors stand to gain from Globus Medical's positioning in a market valuing procedural efficiency. The company's differentiated technologies address musculoskeletal disorders affecting millions, with spinal procedures forming the bulk of revenue. Amid healthcare spending rises, GMED offers exposure to durable tailwinds. With NYSE trading in USD, the stock's 87.21 USD level invites accumulation for those eyeing 25% upside per analyst views. German-speaking investors in Germany, Austria, and Switzerland can access GMED via international brokers, benefiting from US medtech leadership without currency hedging complexities in primary markets. Strategic M&A signals, like post-earnings comments, position Globus for bolt-on acquisitions enhancing biologics and instruments. This appeals to portfolios seeking defensive growth in healthcare. Sector dynamics and competitive edge. Globus operates in medical equipment, supplies, and distribution, focusing on implants, biologics, and instruments for spinal, orthopedic, and neurosurgical uses. Competitors face margin pressures, but Globus's portfolio post-NuVasive integration provides scale advantages. Revenue diversification mitigates procedure volume risks. Key metrics like order backlog and pricing power matter here. Recent earnings confirm pricing stability and utilization gains. US investors value this amid supply chain recoveries and elective surgery rebounds. Analyst 'Outperform' ratings stem from EPS revisions and visibility scores, with Trader and Investor composites positive. This sector-specific strength differentiates GMED. Further reading Further developments, updates, and context on the stock can be explored quickly through the linked overview pages. Risks and open questions post-departure. While the board change appears orderly, uncertainties linger on successor expertise. Medtech firms risk innovation slowdowns without specialized directors. Regulatory hurdles in biologics approvals add layers, demanding vigilant oversight. Insider sales earlier in 2026, including 1.89 million USD in February, raise flags though not unusual post-earnings. Macro risks like reimbursement cuts or procedure deferrals in economic downturns persist. Investors weigh these against 2026 guidance strength. Valuation at current NYSE levels offers a buffer, but volatility tied to clinical trial outcomes remains. US investors should monitor Q1 updates for continuity. Outlook and strategic catalysts ahead. Looking forward, Globus Medical's M&A appetite, reaffirmed in February, could drive accretion via targeted deals. Product launches in enabling technologies promise margin expansion. Analyst targets imply confidence in execution. For US investors, GMED represents a play on musculoskeletal health trends, with NYSE liquidity aiding positioning. German-speaking audiences gain indirect exposure through diversified portfolios. The board refresh may catalyze renewed focus on shareholder returns. Sustained revenue beats and EPS growth position Globus favorably. Monitoring governance evolution will be key as 2026 unfolds. Disclaimer: This is not investment advice. Stocks are volatile financial instruments. Globus Medical-Aktie: Kaufen oder verkaufen?! Neue Globus Medical-Analyse vom 26. März liefert die Antwort: Die neusten Globus Medical-Zahlen sprechen eine klare Sprache: Dringender Handlungsbedarf für Globus Medical-Aktionäre. Lohnt sich ein Einstieg oder sollten Sie lieber verkaufen? In der aktuellen Gratis-Analyse vom 26. März erfahren Sie was jetzt zu tun ist. So schätzen börsenprofis die Aktie Globus Medical Inc ein. Verpasse keine chance mehr. Ob Chancen, Risiken oder neue Signale zur Aktie Globus Medical Inc: trading-notes liefert dir seit 2005 dreimal pro Woche verlässliche Aktien-Impulse zu diesem und vielen weiteren spannenden Aktien-Werten - dreimal pro Woche kostenlos per E-Mail. Für. Immer. Kostenlos. US3795772082 | GLOBUS MEDICAL INC | boerse | 68972449 | bgmi

Yahoo Finance
Mar 10th, 2026
Globus Medical reaffirms $3.18B–3.22B 2026 revenue guidance, signals M&A plans

Globus Medical has raised $120 million in a Series C round, reaffirming its 2026 revenue guidance of $3.18–3.22 billion after reporting fourth-quarter 2025 sales of $826.42 million and net income of $140.59 million. The medical device company also reported 2025 full-year revenue of $2.94 billion and net income of $537.87 million. Management highlighted ongoing interest in tuck-in acquisitions alongside disciplined capital allocation, signalling confidence in its operating model focused on robotics, integration and global expansion. The reaffirmed guidance keeps attention on how quickly robotics adoption and international expansion can translate into consistent earnings. Analysts project revenues could reach $3.4 billion by 2028, though some caution that integration complexity and slower enabling technology adoption could affect these expectations.

The Associated Press
Feb 24th, 2026
Globus Medical reports Q4 sales of $826M, up 26%, and raises 2026 EPS guidance to $4.40-$4.50

Globus Medical, a musculoskeletal technology solutions company, reported fourth quarter 2025 worldwide net sales of $826.4 million, up 25.7% year-over-year, or 24.7% on a constant currency basis. Base business sales, excluding Nevro, reached $726.7 million, up 10.6%. GAAP net income for the quarter was $140.6 million, whilst GAAP diluted earnings per share rose 442.6% to $1.03. Non-GAAP diluted EPS increased 52.1% to $1.28. Full year 2025 sales totalled $2.94 billion, up 16.7%, with GAAP diluted EPS of $3.92, up 425.4%. The company reaffirmed its 2026 revenue guidance of $3.18 billion to $3.22 billion and raised non-GAAP diluted EPS guidance to $4.40-$4.50 from $4.30-$4.40.

GlobeNewswire
Feb 6th, 2025
Globus Medical Acquires Nevro for $250M

Globus Medical will acquire Nevro Corp. in an all-cash deal valued at $250 million, paying $5.85 per share. The acquisition aims to expand Globus Medical's market reach and enhance its neuromodulation technologies. The transaction, approved by both companies' boards, is expected to close in Q2 2025, pending shareholder and regulatory approvals. Globus anticipates 2025 net sales of $2.80 billion to $2.90 billion post-acquisition.